Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial
<h3>Background</h3> The optimal use of various therapeutic combinations for moderate/severe chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the efficacy of two long-acting anti-muscarinic antagonists (LAMA), when combined with an inhaled corticosteroid...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
2015
|
| Online Erişim: | https://doi.org/10.1136/thoraxjnl-2014-206670 https://thorax.bmj.com/content/thoraxjnl/70/6/519.full.pdf |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|